Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Interest Expenses (2021 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Interest Expenses for 9 consecutive years, with $586000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest Expenses fell 42.83% year-over-year to $586000.0, compared with a TTM value of $2.7 million through Sep 2025, down 31.86%, and an annual FY2024 reading of $4.1 million, up 19.89% over the prior year.
  • Interest Expenses was $586000.0 for Q3 2025 at Fennec Pharmaceuticals, down from $594000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $1.0 million in Q2 2024 and bottomed at -$51000.0 in Q3 2021.
  • Average Interest Expenses over 5 years is $635562.5, with a median of $811500.0 recorded in 2023.
  • The sharpest move saw Interest Expenses surged 1350.0% in 2022, then plummeted 43.1% in 2025.
  • Year by year, Interest Expenses stood at -$51000.0 in 2021, then soared by 1892.16% to $914000.0 in 2022, then grew by 0.11% to $915000.0 in 2023, then rose by 5.57% to $966000.0 in 2024, then plummeted by 39.34% to $586000.0 in 2025.
  • Business Quant data shows Interest Expenses for FENC at $586000.0 in Q3 2025, $594000.0 in Q2 2025, and $592000.0 in Q1 2025.